Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NXL

NXL - Nexalin Technology Inc Stock Price, Fair Value and News

$0.61+0.02 (+3.39%)
Market Closed

23/100

NXL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

NXL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.49

Target 3M

$0.55

Target 6M

$0.52

NXL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NXL Price Action

Last 7 days

-1.6%

Last 90 days

-60.1%

Trailing 12 Months

-76.3%

NXL RSI Chart

NXL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NXL Valuation

Market Cap

11.4M

Price/Earnings (Trailing)

-1.31

Price/Sales (Trailing)

23.29

EV/EBITDA

-1.24

Price/Free Cashflow

-2.3

NXL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.49

Target 3M

$0.55

Target 6M

$0.52

NXL Fundamentals

NXL Revenue

Revenue (TTM)

848.9K

Rev. Growth (Yr)

1.09%

Rev. Growth (Qtr)

48.46%

NXL Earnings

Earnings (TTM)

-8.7M

Earnings Growth (Yr)

7.02%

Earnings Growth (Qtr)

-43.98%

NXL Profitability

Operating Margin

94.36%

EBT Margin

-1022.26%

Return on Equity

-182.01%

Return on Assets

-169.31%

Free Cashflow Yield

-43.45%

NXL Investor Care

Shares Dilution (1Y)

45.02%

Diluted EPS (TTM)

-0.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024125.2K139.7K154.2K168.7K
20231.0M716.1K413.4K110.7K
2022438.4K732.7K1.0M1.3M
2021000144.1K
Get all data in R, Python etc through our Historical Stock Data APIs

About Nexalin Technology Inc

NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.
 CEO
 WEBSITEnexalin.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES6

Nexalin Technology Inc Frequently Asked Questions

NXL is the stock ticker symbol of Nexalin Technology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Nexalin Technology Inc is 11.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NXL's fair value in chart for subscribers.

The fair value guage provides a quick view whether NXL is over valued or under valued. Whether Nexalin Technology Inc is cheap or expensive depends on the assumptions which impact Nexalin Technology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NXL.

As of Wed Jan 28 2026, NXL's PE ratio (Price to Earnings) is -1.31 and Price to Sales (PS) ratio is 23.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NXL PE ratio will change depending on the future growth rate expectations of investors.